Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy.
Ioannou N, Hagner PR, Stokes M, Gandhi AK, Apollonio B, Fanous M, Papazoglou D, Sutton LA, Rosenquist R, Amini RM, Chiu H, Lopez-Girona A, Janardhanan P, Awan FT, Jones J, Kay NE, Shanafelt TD, Tallman MS, Stamatopoulos K, Patten PEM, Vardi A, Ramsay AG. Ioannou N, et al. Among authors: hagner pr. Blood. 2021 Jan 14;137(2):216-231. doi: 10.1182/blood.2020006073. Blood. 2021. PMID: 33024998 Free PMC article.
CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.
Hagner PR, Man HW, Fontanillo C, Wang M, Couto S, Breider M, Bjorklund C, Havens CG, Lu G, Rychak E, Raymon H, Narla RK, Barnes L, Khambatta G, Chiu H, Kosek J, Kang J, Amantangelo MD, Waldman M, Lopez-Girona A, Cai T, Pourdehnad M, Trotter M, Daniel TO, Schafer PH, Klippel A, Thakurta A, Chopra R, Gandhi AK. Hagner PR, et al. Blood. 2015 Aug 6;126(6):779-89. doi: 10.1182/blood-2015-02-628669. Epub 2015 May 22. Blood. 2015. PMID: 26002965 Free PMC article. Clinical Trial.
Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
Bjorklund CC, Lu L, Kang J, Hagner PR, Havens CG, Amatangelo M, Wang M, Ren Y, Couto S, Breider M, Ning Y, Gandhi AK, Daniel TO, Chopra R, Klippel A, Thakurta AG. Bjorklund CC, et al. Among authors: hagner pr. Blood Cancer J. 2015 Oct 2;5(10):e354. doi: 10.1038/bcj.2015.66. Blood Cancer J. 2015. PMID: 26430725 Free PMC article.
Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma.
Chiu H, Trisal P, Bjorklund C, Carrancio S, Toraño EG, Guarinos C, Papazoglou D, Hagner PR, Beldi-Ferchiou A, Tarte K, Delfau-Larue MH, Morschhauser F, Ramsay AG, Gandhi AK. Chiu H, et al. Among authors: hagner pr. Br J Haematol. 2019 Apr;185(2):240-253. doi: 10.1111/bjh.15797. Epub 2019 Feb 14. Br J Haematol. 2019. PMID: 30767211 Free PMC article.
Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier.
Carpio C, Bouabdallah R, Ysebaert L, Sancho JM, Salles G, Cordoba R, Pinto A, Gharibo M, Rasco D, Panizo C, Lopez-Martin JA, Santoro A, Salar A, Damian S, Martin A, Verhoef G, Van den Neste E, Wang M, Couto S, Carrancio S, Weng A, Wang X, Schmitz F, Wei X, Hege K, Trotter MWB, Risueño A, Buchholz TJ, Hagner PR, Gandhi AK, Pourdehnad M, Ribrag V. Carpio C, et al. Among authors: hagner pr. Blood. 2020 Mar 26;135(13):996-1007. doi: 10.1182/blood.2019002395. Blood. 2020. PMID: 31977002 Free PMC article.
Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent.
Risueño A, Hagner PR, Towfic F, Fontanillo C, Djebbari A, Parker JS, Drew CP, Nowakowski GS, Maurer MJ, Cerhan JR, Wei X, Ren Y, Lee CW, Couto S, Wang M, Pourdehnad M, Gandhi AK, Trotter MWB. Risueño A, et al. Among authors: hagner pr. Blood. 2020 Mar 26;135(13):1008-1018. doi: 10.1182/blood.2019002414. Blood. 2020. PMID: 31977005 Free PMC article.
31 results